Free Biopharma Daily Stock Updates - 04/21/21

$XBI $132.77 +3.49%

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

Covid Updates

$OCGN +6.5% Co-development partner shared positive Phase 3 results on COVAXIN. source

$DVAX +5.0% VA2001 Phase 3 trial initiated; expect data and regulatory submission in autumn 2021. source

$TRVN +2.9% TRV027 COVID-19 asset selected for inclusion in international, multi-site, Phase 2/3 trial. source

Pipeline Updates

$SNDX +10.7% Announces positive interim data in Phase 1 portion of AUGMENT-101 trial. source

$EVFM +10.6% Will present at NCODA 2021 National Forum 4/28-30. source

$ORMP +10.6% Will present at Alliance Global Partners on 4/26/2021. source

$ALLO +7.8% ALLO-715 granted RMAT Designation. source

$PHVS +4.5% IND accepted for additional study with PHVS416. source

$VIR -1.0% and $VBIV +7.7% Phase 2 combination trial of VBI-2601 with VIR-2218 initiated dosing. source

$RVMD +5.6% Dosed first patient in RMC-5552 Phase 1/1b trial. source

$TGTX +1.9% ULTRA-V Phase 3 trial initiated; results from Phase 1 trial expected later in 2021. source

$SLS +9.3% President and CEO discusses Phase 3 asset GPS as a monotherapy. source

Finance Updates

$EOLS +11.1% Commenced proposed public offering of common stock. source